GILD Q4 2025 Earnings Analysis
Listen On
Available In
Key Highlights
- Revenue and earnings analysis for Q4 2025
- Key financial metrics and performance indicators
- Management guidance and outlook commentary
- Market position and competitive analysis
- AI-generated insights and analysis
Transcript
// Full episode scriptBeta Finch Podcast Script: Gilead Q4 2025 Earnings
Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're unpacking Gilead Sciences' Q4 2025 results - and folks, there's a lot to dig into here. Before we jump in though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Thanks Alex. And what a quarter this was for Gilead! The biotech giant just wrapped up what CEO Dan O'Day called "a remarkable year" - and the numbers certainly back that up. They hit $28.9 billion in total product sales for 2025, beating their guidance range and showing some serious momentum heading into 2026.
Absolutely, Jordan. Let's break down those headline numbers first. Total product sales came in at $7.9 billion for Q4, up 5% year-over-year. But here's what caught my attention - when you strip out their COVID drug Veclury, which has been declining as expected, their base business actually grew 7% in the quarter and 4% for the full year.
That's a key distinction, Alex. And speaking of key numbers, their HIV business - which is still their cash cow - delivered $20.8 billion in sales for the year, up 6%. But here's where it gets interesting: they faced an estimated $900 million headwind from Medicare Part D redesign changes. Without that policy impact, their HIV business would have grown 10%.
That Medicare Part D impact is huge context, Jordan. For listeners who might not be familiar, this was a policy change that affected how drug pricing works for seniors on Medicare. So when Gilead says their underlying HIV business grew 10%, that's actually pretty impressive growth for what's considered a mature market.
Exactly. And let's talk about the star of the show - YES2GO. This is their twice-yearly injectable HIV prevention drug that launched in 2025, and it's already showing blockbuster potential. They did $150 million in sales for the year, and here's the kicker - they're guiding for $800 million in 2026.
That's more than a 5x increase, Jordan. During the Q&A, analysts were really pressing on how realistic that number is. Management seems confident though, citing 90% payer coverage already - including all major insurers - with about 90% of covered patients getting it with zero co-pay.
The coverage piece is critical, Alex. Commercial launch is one thing, but getting insurance companies to pay for a premium-priced injectable is another. The fact that they hit their 90% coverage target well ahead of their one-year timeline suggests the value proposition is resonating with payers.
Let's shift to their pipeline, because this is where things get really interesting for long-term investors. They have four potential product launches coming in 2026, plus five Phase III data readouts across HIV, cancer, and liver disease.
Right, and this diversification strategy is really starting to pay off. Their cancer drug Trodelvy grew 6% to $1.4 billion, and they just got positive Phase III data that could expand it from second-line to first-line treatment in triple-negative breast cancer. That's potentially doubling the addressable market.
And Trodelvy isn't their only oncology play. They're preparing to launch something called Anidocel - a CAR-T therapy for multiple myeloma. The clinical data looks strong with a 96% overall response rate and what they're calling a "best-in-disease" safety profile.
The safety piece is huge in CAR-T, Alex. These are powerful but potentially toxic treatments. If they can deliver the efficacy without the severe side effects, that's a real competitive advantage. They're targeting a second-half 2026 launch for the fourth-line setting.
Now let's talk financials beyond just revenue. They delivered $8.15 in non-GAAP earnings per share for 2025, right in line with guidance. For 2026, they're guiding $8.45 to $8.85 per share, which represents solid growth.
And Alex, they returned $5.9 billion to shareholders in 2025 - that's about 63% of their free cash flow through dividends and buybacks. They're committed to returning at least 50% going forward, which should appeal to income-focused investors.
One thing that stood out to me in the Q&A was the discussion around business development. CEO O'Day mentioned they spend about $1 billion annually on "normal course" deals - smaller partnerships and acquisitions. But for larger M&A, they're being disciplined.
That disciplined approach makes sense given their pipeline strength, Alex. With no major patent cliff until 2036 and up to 10 launches through 2027, they're not desperate for deals. They can be selective and focus on quality over quantity.
Speaking of 2026 guidance, they're expecting total product sales of $29.6 to $30 billion, which represents solid growth despite some headwinds. They mentioned about a 2% impact from recent drug pricing agreements and potential Affordable Care Act changes.
Those policy headwinds are worth watching, Alex. The pharmaceutical industry continues to face pricing pressure, but Gilead seems to be managing through it with innovation and portfolio diversification. Their base business guidance of 4-5% growth ex-Veclury is respectable in this environment.
Let's talk about what this means for investors going forward, Jordan. On the positive side, you have a company that's successfully diversifying beyond HIV, strong cash generation, shareholder-friendly capital allocation, and a robust pipeline with near-term catalysts.
Absolutely. The YES2GO launch trajectory will be key to watch - if they can hit that $800 million 2026 target, it validates their ability to innovate in HIV prevention. The cancer expansion with Trodelvy and potential Anidocel launch could open up significant new revenue streams.
The risks I'd highlight are continued pricing pressure across the industry, execution risk on multiple simultaneous launches, and the fact that they're still heavily dependent on HIV for cash flow, even with diversification efforts.
That's fair, Alex. But looking at their patent cliff protection through 2036, that gives them a long runway to continue this diversification. And with their disciplined M&A approach, they have the financial flexibility to add assets if needed.
Before we wrap up, Jordan, what's your key takeaway from this earnings call?
I think this represents a company in transition, Alex. They're moving from being primarily an HIV company to a more diversified biotech with meaningful positions in oncology and liver disease. The execution on YES2GO and the upcoming launches will be critical proof points.
I agree. And for investors, it's worth noting that everything discussed today is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence. That wraps up our breakdown of Gilead's Q4 2025 earnings. The biotech giant is entering 2026 with momentum across multiple franchises and a pipeline that could reshape their business over the next few years. Thanks for tuning in to Beta Finch, and we'll see you next time when we decode the next set of earnings that move markets.